Evidence map›Paper›PMID 31006073›Full record

ArticleJournal of endocrinological investigation2019

Impact of CFTR-modulating drugs on GH-IGF-1 axis impairment in adult patients with cystic fibrosis.

C Pascucci, R V De Biase, D Savi, S Quattrucci, L Gnessi, C Lubrano, A Lenzi

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of endocrinological investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

C PascucciSection of Medical Pathophysiology, Endocrinology, Department Experimental Medicine, Sapienza University of Rome, 00161, Rome, Italy. chiarapascucci@libero.it.
R V De BiaseCystic Fibrosis Unit, Bambino Gesù Children's Hospital, Rome, Italy.
D SaviCystic Fibrosis Unit, Bambino Gesù Children's Hospital, Rome, Italy.
S QuattrucciPediatrics Department, Cystic Fibrosis Regional Center, Sapienza University of Rome, Rome, Italy.
L GnessiSection of Medical Pathophysiology, Endocrinology, Department Experimental Medicine, Sapienza University of Rome, 00161, Rome, Italy.
C LubranoSection of Medical Pathophysiology, Endocrinology, Department Experimental Medicine, Sapienza University of Rome, 00161, Rome, Italy.
A LenziSection of Medical Pathophysiology, Endocrinology, Department Experimental Medicine, Sapienza University of Rome, 00161, Rome, Italy.
Sapienza University of Rome · ITBambino Gesù Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA new class of drugs in the treatment of cystic fibrosis (CF) includes two agents: lumacaftor, which corrects CFTR channel protein, and ivacaftor, which increases CFTR channel activity. In our previous study we recruited 50 stable adults with CF and 16 of them showed growth hormone deficit (GHD): 7 patients severe and 9 patients partial GHD. MATERIAL AND

methodsWe decided to re-evaluate ten patients with the GHRH + arginine test of whom only five were treated with lumacaftor/ivacaftor.

resultsAll CF patients in therapy with lumacaftor/ivacaftor showed a marked improvement in GHD. Two patients moved from a severe GHD to a normal response to the GH/IGF-1 axis test, and three patients who had partial GHD moved to normal response.

conclusionThe pituitary gland may be damaged by CF disease and could benefit of the action of correcting drugs.

Indexed as

MutationAdultAminophenolsAminopyridinesBenzodioxolesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsFemaleFollow-Up StudiesGrowth DisordersHuman Growth HormoneHumansInsulin-Like Growth Factor IMaleMiddle AgedAminophenolsAminopyridinesBenzodioxolesCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsHuman Growth HormoneIGF1 protein, humanInsulin-Like Growth Factor Ilumacaftor, ivacaftor drug combinationQuinolonesAdult patientsCystic fibrosisGrowth hormoneInsulin-like growth factor-1IvacaftorLumacaftor

Identifiers

PMID31006073
OpenAlexW2939525957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.